Publication

Anakinra usage in febrile infection related epilepsy syndrome: an international cohort

Downloadable Content

Persistent URL
Last modified
  • 05/22/2025
Type of Material
Authors
    Yi-Chen Lai, Baylor College of Medicine/Texas Children's HospitalEyal Muscal, Baylor College of Medicine/Texas Children's HospitalElizabeth Wells, Children's National Health SystemNikita Shukla, Baylor College of Medicine/Texas Children's HospitalKrista Eschbach, University of ColoradoKi Hyeong Lee, AdventHealthMairos Kaliakatsos, Great Ormond Street HospitalNevedita Desai, Great Ormond Street HospitalRonny Wickstrom, Karolinska University HospitalMaurizio Viri, University Hospital Maggiore della CaritàElena Freri, FONDAZIONE IRCCS ISTITUTO NEUROLOGICO "CARLO BESTA"Tiziana Granata, FONDAZIONE IRCCS ISTITUTO NEUROLOGICO "CARLO BESTA"Srishti Nangia, New York Presbyterian Hospital‐Weill Cornell MedicalRobertino Dilena, Fondazione IRCCS Ca' Granda Ospedale Maggiore PoliclinicoAndreas Brunklaus, Royal Hospital for ChildrenMark S. Wainwright, University of WashingtonMark P. Gorman, Harvard Medical SchoolCoral M. Stredny, Harvard Medical SchoolAbdurhman Asiri, Prince Sultan Medical Military City (PSMMC)Khalid Hundallah, Prince Sultan Medical Military City (PSMMC)Asif Doja, University of OttawaEric Payne, Alberta Children’s HospitalElaine Wirrell, Mayo ClinicSookyong Koh, Emory UniversityJessica L. Carpenter, Children's National Health SystemJames Riviello, Baylor College of Medicine/Texas Children's Hospital
Language
  • English
Date
  • 2020-12-04
Publisher
  • WILEY
Publication Version
Copyright Statement
  • © 2020 The Authors.
License
Final Published Version (URL)
Title of Journal or Parent Work
Volume
  • 7
Issue
  • 12
Start Page
  • 2467
End Page
  • 2474
Abstract
  • Febrile-infection related epilepsy syndrome (FIRES) is a devastating neurological condition characterized by a febrile illness preceding new onset refractory status epilepticus (NORSE). Increasing evidence suggests innate immune dysfunction as a potential pathological mechanism. We report an international retrospective cohort of 25 children treated with anakinra, a recombinant interleukin-1 receptor antagonist, as an immunomodulator for FIRES. Anakinra was potentially safe with only one child discontinuing therapy due to infection. Earlier anakinra initiation was associated with shorter duration of mechanical ventilation, ICU and hospital length of stay. Our retrospective data lay the groundwork for prospective consensus-driven cohort studies of anakinra in FIRES.
Author Notes
  • Eyal Muscal
Keywords
Research Categories
  • Engineering, Biomedical
  • Biology, Neuroscience

Tools

Relations

In Collection:

Items